Literature DB >> 21873666

Mathematical projection model of visual loss due to fuchs corneal dystrophy.

Shin Hatou1, Shigeto Shimmura, Jun Shimazaki, Tomohiko Usui, Shiro Amano, Hideaki Yokogawa, Akira Kobayashi, Xiaodong Zheng, Atsushi Shiraishi, Yuichi Ohashi, Tsutomu Inatomi, Kazuo Tsubota.   

Abstract

PURPOSE. To devise a mathematical disease classification model for eyes with primary guttata cornea, on the bases of endothelial loss trajectory and probability of advanced disease. METHODS. A series of 1971 patients (3281 eyes), some with and some without guttata corneas, undergoing specular microscopy were retrospectively reviewed. The eyes were classified into four stages; stage 0, without guttae; 1, guttata cornea without edema; 2, mild Fuchs' corneal dystrophy (FCD); and 3, severe FCD, according to clinical records, and patient age and corneal endothelial cell density (ECD) were plotted. Nonparametric density smoothing was used to create a contour map, and a best-fit curve for ECD loss was calculated. The relation between ECD decrease rate and the stages were evaluated. RESULTS. Endothelial decrease rate in stage 0 was 0.44%/year, which was compatible with that of normal eyes reported in previous studies. Decrease rates of stages 1, 2, and 3 were 0.81%, 2.65%, and 3.08%/ year, respectively. The age-ECD loss curves of 1.40%/year (ECO(1.4)) and 2.00%/year (ECO(2.0)) further divided stage 1 into three subgroups; stage 1a, asymptomatic guttata cornea; 1b, borderline guttata cornea; and 1c, pre-FCD. The ECO(2.0) cutoff line differentiated eyes with FCD from those without edema with a sensitivity and specificity of >90%. Stage 1c eyes were below ECO(2.0) and had a decrease rate as high as FCD. CONCLUSIONS. This mathematical model can be used to predict the prognosis of patients with primary guttata cornea.

Entities:  

Mesh:

Year:  2011        PMID: 21873666     DOI: 10.1167/iovs.11-8040

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Association of smoking and other risk factors with Fuchs' endothelial corneal dystrophy severity and corneal thickness.

Authors:  Xiaolin Zhang; Robert P Igo; Jeremy Fondran; V Vinod Mootha; Matt Oliva; Kristin Hammersmith; Alan Sugar; Jonathan H Lass; Sudha K Iyengar
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-27       Impact factor: 4.799

2.  Objective assessment of the corneal endothelium in Fuchs' endothelial dystrophy.

Authors:  Jay W McLaren; Lori A Bachman; Katrina M Kane; Sanjay V Patel
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-26       Impact factor: 4.799

3.  Changes in Keratocyte Density and Visual Function Five Years After Laser In Situ Keratomileusis: Femtosecond Laser Versus Mechanical Microkeratome.

Authors:  Jay W McLaren; William M Bourne; Leo J Maguire; Sanjay V Patel
Journal:  Am J Ophthalmol       Date:  2015-04-11       Impact factor: 5.258

4.  [Corneal collagen cross-linking with riboflavin and ultraviolet-A light in progressive keratoconus. Results after 10-year follow-up].

Authors:  A Theuring; E Spoerl; L E Pillunat; F Raiskup
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

5.  Relationship of Fuchs endothelial corneal dystrophy severity to central corneal thickness.

Authors:  Laura J Kopplin; Katie Przepyszny; Brian Schmotzer; Karen Rudo; Denise C Babineau; Sanjay V Patel; David D Verdier; Ula Jurkunas; Sudha K Iyengar; Jonathan H Lass
Journal:  Arch Ophthalmol       Date:  2012-04

6.  Fuchs' endothelial corneal dystrophy: subjective grading versus objective grading based on the central-to-peripheral thickness ratio.

Authors:  Daniel J Repp; David O Hodge; Keith H Baratz; Jay W McLaren; Sanjay V Patel
Journal:  Ophthalmology       Date:  2013-01-28       Impact factor: 12.079

7.  Skin-Derived Precursors as a Source of Progenitors for Corneal Endothelial Regeneration.

Authors:  Emi Inagaki; Shin Hatou; Kazunari Higa; Satoru Yoshida; Shinsuke Shibata; Hideyuki Okano; Kazuo Tsubota; Shigeto Shimmura
Journal:  Stem Cells Transl Med       Date:  2017-02-06       Impact factor: 6.940

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.